Tempus in the news

CHICAGO and ATLANTA, December 11, 2019 — Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announced the acquisition of AKESOgen, an industry-leading commercial laboratory facility and provider of genomics and clinical trial precision medicine services based in Atlanta. AKESOgen is an integrated gen...

Eric Lefkofsky and Tom Mihaljevic discuss Tempus and the future of precision medicine. Video linked here.    

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announced that Dr. Scott Gottlieb, MD, has joined its Board of Directors. Dr. Gottlieb will serve as an advisor to Tempus and its leadership team, leveraging his vast experience as a...

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today published a study in Nature Biotechnology, one of the industry’s leading peer-reviewed, scientific journals, surrounding its xT platform. The study, which focuses on 500 patient samples across diverse tumor types ana...

Geisinger announced today a new multi-year partnership with Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. The collaboration aims to use the power of machine learning and artificial intelligence to build new precision medicine tools for cardiology that will enable...

Tempus, a technology company advancing precision medicine through the collection and analysis of molecular and clinical data at scale, announced today the appointment of Lauren Silvis as its Senior Vice President of External Affairs. Silvis will oversee regulatory, public policy and government affairs, operating from Tempus’ office to...

Tempus, a technology company advancing precision medicine through the collection and analysis of molecular and clinical data at scale, announced today that it is providing its de-identified datasets via a data subscription, enabling researchers to leverage unique, longitudinally-updated clinical and molecular data at scale, which will help accelerate...

Tempus, a technology company advancing precision medicine through the collection and analysis of molecular and clinical data at scale, announces the appointment of Joel Dudley, PhD, as its Senior Vice President of Research. In his role, Dr. Dudley is responsible for leading Tempus’s research and development efforts...

Forbes | Noah Kirsch & Michela Tindera Eric Lefkofsky hasn’t taken a science class since college. But as he meanders through the Chicago lab of Tempus, his medical startup, he presents an air of expertise. “One thing you can see right off the bat is the purple staining of this cell,” he says, pointing to the pathology slid...

Tempus, a technology company advancing precision medicine through the collection and analysis of molecular and clinical data at scale announced today that it was selected by Leidos Biomedical Research Inc. (Leidos Biomed) to abstract and structure follow-up clinical data for The Cancer Genome Atlas (TCGA) Project for submission...